报告40例晚期乳腺癌初始应用高剂量表阿霉素(Epirubicin)化疗的疗效及毒性。全组中位年龄52岁(29～65岁);雌激素受体阳性10例,阴性15例,不明者15例;已绝经者30例,未绝经者10例;先前未接受过治疗者9例,接受过化疗者5例,接受过内分泌治疗者28例。治疗前,患者的WBC>3.5×10~9/L,Pt>100×10~9/L,肝肾功能正常,无中枢神经系统侵犯、活动性感染、心衰病史、心律失常、高血压及缺血性心脏病。 The efficacy and toxicity of high-dose epirubicin chemotherapy were initially reported in 40 patients with advanced breast cancer. The median age of the whole group was 52 years old (29-65 years old); 10 cases were estrogen receptor positive, 15 cases were negative, 15 cases were unexplained; 30 cases were postmenopausal, and 10 cases were non-menopause; previously untreated 9 For example, 5 patients received chemotherapy and 28 received endocrine therapy. Before treatment, the patient’s WBC> 3.5 × 10 ~ 9 / L, Pt> 100 × 10 ~ 9 / L, normal liver and kidney function, no central nervous system violations, active infection, history of heart failure, arrhythmia, hypertension and Ischemic heart disease.